November 2024 - Page 7 of 17

Release – GDEV Announces Unaudited Results for the Third quarter and the First Nine Months of 2024

Posted on November 14, 2024November 14, 2024 by aweinsoff@channelchek.com

November 14, 2024 08:00 ET

LIMASSOL, Cyprus, Nov. 14, 2024 (GLOBE NEWSWIRE) — GDEV Inc. (NASDAQ: GDEV), an international gaming and entertainment company (“GDEV” or the “Company”) released its unaudited financial and operational results for the third quarter and first nine months ended September 30, 2024.

GDEV CEO, Andrey Fadeev noted: ”In Q3, despite industry pressure, we delivered sequential revenue growth.

We also kept executing our strategy and moved forward with the transformation of our core products. The updates are rolling across our main franchises to elevate the game experience, adding new modern features to what players already love. We are not after quick wins – it’s about innovating in a way that sets us up for lasting impact.

We are pleased to have established an at-the-market offering (“the ATM”) in September as an important step towards increasing the free float and liquidity of our stock. Under the ATM, the Company may sell up to 1,757,026 ordinary shares of the Company, held in treasury.¹. We expect the ATM to be effective until we sell all the treasury shares or for 3 years from the effective date of the Registration Statement whichever is earlier.

I’m also thrilled to share that our former independent director Olga Loskutova has recently joined the management team as our new Chief Operating Officer. However, the board remains within best practices in terms of INED majority directors and one third women. As COO, Olga will be well positioned to enable us to reach our ambitious strategic goals. By staying focused, we’re building momentum for sustainable growth that will shape our future.”

Third quarter 2024 financial highlights:

Revenue of $111 million, growing 5% quarter-over-quarter, while decreased by 9% year-over-year.
Selling and marketing expenses of $52 million, grew by 22% year-over-year and by 10% quarter-on-quarter due to the execution of our strategy to scale the business.
We continue to adhere to our disciplined approach towards costs: game operation cost declined by 6% year-over-year while general and administrative expenses declined by 9% year-over-year.
Profit for the period, net of tax of $15 million in Q3 2024 decreased vs. $24 million in Q3 2023 due to scaling of selling and marketing expenses, among other factors.
Adjusted EBITDA of $16 million in line with the previous quarter.²
European share of bookings increased by 4 p.p. to 30%, driven by effective and more targeted user acquisition campaigns in the region.
Cash position of $153 million, compared to $140 million at the end of Q2 2024, providing broad opportunities for further expansion³.

Third quarter and first nine months 2024 financial performance in comparison

US$ million	Q3 2024	Q3⁴2023	Change (%)	9M 2024	9M 2023	Change (%)
Revenue	111	121	(9%)	323	355	(9%)
Platform commissions	(24)	(28)	(13%)	(70)	(84)	(16%)
Game operation cost	(13)	(13)	(6%)	(38)	(42)	(10%)
Selling and marketing expenses	(52)	(43)	22%	(163)	(172)	(5%)
General and administrative expenses	(7)	(8)	(9%)	(23)	(24)	(1%)
Profit for the period, net of tax	15	24	(38%)	28	35	(20%)
Adjusted EBITDA	16	29	(44%)	30	33	(9%)
Cash flows generated from/(used in) operating activities	12	8	45%	24	8	197%

Third quarter 2024 financial performance

In the third quarter of 2024, our revenue decreased by $11 million (or 9%) year-over-year and amounted to $111 million. While bookings for the third quarter of 2024 decreased by $9 million, the decrease in revenue compared to Q3 2023 was amplified by a decrease in the recognition of deferred revenues associated with bookings recorded in periods prior to Q3 2024: in Q3 2024, $57 million of revenues resulted from the bookings recorded prior to Q3 2024 compared to $65 million of revenues booked in Q3 2023 which resulted from bookings recorded prior to Q3 2023. Revenues reported in Q3 2023, in turn, were impacted by the recognition of record high bookings generated in 2021. The decrease in revenues also reflects the increasing portion of our bookings in Q3 2024 that are required to be recognized as deferred revenue in later periods, as a greater proportion was generated from our PC platform, where players’ lifespan tends to be higher compared with other platforms.

Platform commissions decreased by $4 million (or 13%) in the third quarter of 2024 compared to the same period in 2023, driven by a 9% decrease in revenues generated from in-game purchases, and amplified by growth of revenues derived from PC platforms which are associated with lower commissions.

Game operation cost remained relatively stable at the level of $13 million both in the third quarter of 2024 and 2023.

Selling and marketing expenses in the third quarter of 2024 increased by $9 million, amounting to $52 million. The increase is due to our strategy of scaling our business together with our experiments across various channels, aimed at optimizing future marketing investments.

General and administrative expenses remained relatively stable at $7 million in Q3 2024 compared with $8 million in Q3 2023.

As a result of the factors above together with, among others, a loss resulting from a change in fair value of share warrant obligation of nil in Q3 2024 vs. $0.8 million in Q3 2023 and decrease of finance expenses in Q3 2024 vs Q3 2023 by $3.7 million, we recorded a profit for the period, net of tax, of $15 million compared with $24 million in the same period of 2023. Adjusted EBITDA in Q3 2024 amounted to $16 million, a decrease of $13 million compared with the same period in 2023.

Cash flows generated from operating activities were $12 million in the third quarter of 2024 compared with $8 million in the same period of 2023.

Third quarter 2024 operational performance

	Q3 2024	Q3 2023	Change (%)	9M 2024	9M 2023	Change (%)
Bookings ($ million)	93	102	(8%)	310	316	(2%)
Bookings from in-app purchases	87	94	(8%)	288	292	(1%)
Bookings from advertising	7	8	(13%)	22	23	(8%)
Share of advertising	7.1%	7.4%	(0.3 p.p)	7.0%	7.4%	(0.4 p.p.)
MPU (thousand)	314	375	(16%)	359	383	(6%)
ABPPU ($)	92	84	10%	89	85	5%

Bookings declined to reach $93 million in the third quarter 2024 compared with $102 million in the same period of 2023. The decline is primarily due to a decline in monthly paying users by 16% in Q3 2024 vs. the same quarter last year partially offset by an increase in ABPPU.

The share of advertisement sales as a percentage of total bookings decreased in the third quarter of 2024 to reach 7.1% compared to 7.4% in the respective period of 2023. This decline was primarily driven by a global trend of declining CPM rates for advertising in 2024.

Split of bookings by platform	Q3 2024	Q3 2023	9M 2024	9M 2023
Mobile	62%	63%	60%	63%
PC	38%	37%	40%	37%

In the third quarter of 2024, the share of PC versions of our games increased by 1 p.p. compared with the same period of 2023.

Split of bookings by geography	Q3 2024	Q3 2023	9M 2024	9M 2023
US	34%	35%	34%	36%
Asia	22%	23%	22%	24%
Europe	30%	26%	30%	25%
Other	14%	16%	14%	15%

Our split of bookings by geography in the third quarter of 2024 vs. the respective period of 2023 remained broadly similar, with a certain increase in the share of Europe bookings.

Note:

Due to rounding, the numbers presented throughout this release may not precisely add up to the totals. The period-over-period percentage changes are based on the actual numbers and may therefore differ from the percentage changes if those were to be calculated based on the rounded numbers.

The figures in this release are unaudited.

Webcast details

To listen to the audio webcast with supplementary slides please follow the link. Prepared remarks are available on gdev.inc.

About GDEV

GDEV is a gaming and entertainment holding company, focused on development and growth of its franchise portfolio across various genres and platforms. With a diverse range of subsidiaries including Nexters and Cubic Games, among others, GDEV strives to create games that will inspire and engage millions of players for years to come. Its franchises, such as Hero Wars, Island Hoppers, Pixel Gun 3D and others have accumulated over 550 million installs and $2.5 bln of bookings worldwide. For more information, please visit www.gdev.inc

Contacts:

Investor Relations
Roman Safiyulin | Chief Corporate Development Officer
investor@gdev.inc

Cautionary statement regarding forward-looking statements

Certain statements in this press release may constitute “forward-looking statements” for purposes of the federal securities laws. Such statements are based on current expectations that are subject to risks and uncertainties. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements.

The forward-looking statements contained in this press release are based on the Company’s current expectations and beliefs concerning future developments and their potential effects on the Company. There can be no assurance that future developments affecting the Company will be those that the Company has anticipated. Forward-looking statements involve a number of risks, uncertainties (some of which are beyond the Company’s control) or other assumptions. You should carefully consider the risks and uncertainties described in the “Risk Factors” section of the Company’s 2023 Annual Report on Form 20-F, filed by the Company on April 29, 2024, and other documents filed by the Company from time to time with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of the Company’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

Presentation of Non-IFRS Financial Measures

In addition to the results provided in accordance with IFRS throughout this press release, the Company has provided the non-IFRS financial measure “Adjusted EBITDA” (the “Non-IFRS Financial Measure”). The Company defines Adjusted EBITDA as the profit/loss for the period, net of tax as presented in the Company’s financial statements in accordance with IFRS, adjusted to exclude (i) goodwill and investments in equity accounted associates’ impairment, (ii) loss on disposal of subsidiaries, (iii) income tax expense, (iv) other financial income, finance income and expenses other than foreign exchange gains and losses and bank charges, (v) change in fair value of share warrant obligations and other financial instruments, (vi) share of loss of equity-accounted associates, (vii) depreciation and amortization, (viii) share-based payments expense and (ix) certain non-cash or other special items that we do not consider indicative of our ongoing operating performance. The Company uses this Non-IFRS Financial Measure for business planning purposes and in measuring its performance relative to that of its competitors. The Company believes that this Non-IFRS Financial Measure is a useful financial metric to assess its operating performance from period-to-period by excluding certain items that the Company believes are not representative of its core business. This Non-IFRS Financial Measure is not intended to replace, and should not be considered superior to, the presentation of the Company’s financial results in accordance with IFRS. The use of the Non-IFRS Financial Measure terms may differ from similar measures reported by other companies and may not be comparable to other similarly titled measures.

Reconciliation of the profit for the period, net of tax to the Adjusted EBITDA

US$ million	Q3 2024	Q3 2023	9M 2024	9M 2023
Profit for the period, net of tax	15	24	28	35
Adjust for:
Income tax expense	1	2	3	3
Adjusted finance (income)/expenses⁵	(2)	0.9	(6)	(2)
Change in fair value of share warrant obligations and other financial instruments	—	0.8	(0.3)	(10)
Share of loss of equity-accounted associates	—	—	—	0.5
Depreciation and amortization	2	2	5	5
Share-based payments	0.7	0.7	1	2
Adjusted EBITDA	16	29	30	33

^{_______________________________}¹ Pursuant to the Company’s registration statement filed with the SEC on Form F-3 (Registration No. 333-282062) and related prospectus, which was filed with the Securities and Exchange Commission on September 12, 2024.
² For more information, see section titled “Presentation of Non-IFRS Financial Measures” in the last two pages of this report, including the reconciliation of the profit for the period, net of tax to the Adjusted EBITDA.
³ The amounts include investments in liquid high quality securities.
⁴ The amounts presented for the three and nine months ended September 30, 2023 may be different to those previously reported for these periods earlier as starting from Q1 2024 the Company reports depreciation and amortization expenses by function as a part of game operation cost, selling and marketing expenses, and general and administrative expenses in accordance with IAS 1.
⁵ Adjusted finance income/expenses consist of other financial income, finance income and expenses other than foreign exchange gains and losses and bank charges, net.

Release – PDS Biotech Provides Clinical Programs Update and Reports Third Quarter 2024 Financial Results

Posted on November 14, 2024November 14, 2024 by aweinsoff@channelchek.com

Research News and Market Data on PDSB

Conference call and webcast today at 8:30 a.m. Eastern Time

PRINCETON, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today provided a business update and reported financial results for the third quarter of 2024.

“Since our last update in August, we have been actively engaged with investors and clinicians to discuss our strategy and funding requirements for our VERSATILE-003 Phase 3 trial of Versamune^® HPV + pembrolizumab compared to pembrolizumab as a potential treatment for first-line recurrent/metastatic HPV16-positive head and neck squamous cell cancer (HNSCC),” said Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech. Dr. Bedu-Addo further noted that “based on investor feedback, discussions with key opinion leaders involved with the study and other experts, we have made minor modifications to the VERSATILE-003 trial design to reduce the overall cost and time required to achieve an interim data readout and trial completion.”

With submission of the updated Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) this week, the Company expects the FDA clearance decision by mid-December, allowing the Company to initiate site activation in the first quarter of 2025.

“Elsewhere in our pipeline, we were pleased with the data from the IMMUNOCERV Phase 2 clinical trial evaluating Versamune^® HPV with chemoradiation to treat locally advanced cervical cancer presented at the American Society for Radiation Oncology (ASTRO) annual meeting. The presented data demonstrated promising clinical activity and a compelling safety profile. Based on continued research in various HPV-positive cancers conducted by PDS Biotech and independent researchers who recognize its potential, Versamune^® HPV appears to work in combination with a variety of therapeutic agents to generate clinical responses and promote improved survival in patients with favorable toxicity. We are exploring the next steps in the development of Versamune^® HPV for cervical cancer,” concluded Dr. Bedu-Addo.

Recent Developments

Update to Phase 3 VERSATILE-003 Trial Design in HPV16-positive first-line recurrent and/or metastatic HNSCC
- Updated trial design to include approximately 350 patients
- VERSATILE-002 results have shown broadly improving clinical responses across multiple parameters with increases in patient size and duration of patient follow up over the last year, demonstrating durability of the anti-tumor responses
- The design, which is informed by the observed durability of the clinical responses, retains statistical power and remains within the confines of our agreement with the FDA on registrational design
- Design maintains 2:1 randomization and median overall survival as primary endpoint
- Design imparts potential for earlier interim readouts and study completion
- Design presents potential for reduced execution costs
- Amended IND (updated design) submitted November 2024
In September 2024, we provided updated results from our VERSATILE-002 Phase 2 clinical trial in recurrent and/or metastatic HPV16-positive HNSCC patients treated with the combination of Versamune^® HPV and pembrolizumab presented at European Society for Medical Oncology (ESMO) Congress 2024 by Jared Weiss, M.D., Section Chief of Thoracic and Head/Neck Oncology, Professor of Medicine at the University of North Carolina, and principal investigator of the VERSATILE-002 clinical trial. Press release here.
In October 2024, we provided updated results from our IMMUNOCERV Phase 2 clinical trial in locally advanced cervical cancer patients treated with Versamune^® HPV and chemoradiotherapy presented at the ASTRO Annual Meeting by Adam Grippin, M.D., Ph.D., The University of Texas MD Anderson Cancer Center. Press release here.
Ravi A. Madan, M.D., Head, Prostate Cancer Clinical Research Section, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, part of the U.S. National Institutes of Health presented the rationale and design of recurrent prostate cancer trial combining Xtandi^® + PDS01ADC vs Xtandi^® alone during an oral presentation at the 12^th Annual Meeting of the International Cytokine and Interferon Society, October 2024. Press release here.

Third Quarter 2024 Financial Results
Reported net loss was approximately $10.7 million, or $0.29 per basic share and diluted share, for the three months ended September 30, 2024, compared to a net loss of $10.8 million, or $0.35 per basic share and diluted share, for the three months ended September 30, 2023. The decrease was primarily due to lower operating expenses.

Research and development expenses increased to approximately $6.8 million for the three months ended September 30, 2024, from $6.4 million for the three months ended September 30, 2023. The increase of $0.4 million was primarily attributable to higher manufacturing expenses, partially offset by lower clinical costs and personnel expenses.

General and administrative expenses decreased to approximately $3.4 million for the three months ended September 30, 2024, from approximately $4.1 million for the three months ended September 30, 2023. The decrease of $0.7 million was primarily attributable to lower personnel costs and professional fees.

Total operating expenses decreased to approximately $10.2 million for the three months ended September 30, 2024, from $10.5 million for the three months ended September 30, 2023.

Net interest expenses increased to approximately $0.5 million for the three months ended September 30, 2024, from $0.3 million for the three months ended September 30, 2023.

Cash and cash equivalents as of September 30, 2024 totaled approximately $49.8 million.

Conference Details

Date: November 14, 2024
Time: 8:30 a.m. ET
Dial-in 1-877-704-4453 or 1-201-389-0920
Webcast Registration: Click Here
Call Me™ Registration: Click Here (Available 15 minutes prior to call)

About PDS Biotechnology

PDS Biotechnology is a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines. The Company plans to initiate a pivotal clinical trial to advance its lead program in advanced HPV16-positive head and neck squamous cell cancers. PDS Biotech’s lead investigational targeted immunotherapy Versamune^® HPV is being developed in combination with a standard-of-care immune checkpoint inhibitor, and also in a triple combination including PDS01ADC, an IL-12 fused antibody drug conjugate (ADC), and a standard-of-care immune checkpoint inhibitor.

For more information, please visit www.pdsbiotech.com

Forward Looking Statements

This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the “Company”) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Company’s management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” “forecast,” “guidance”, “outlook” and other similar expressions among others. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the Company’s ability to protect its intellectual property rights; the Company’s anticipated capital requirements, including the Company’s anticipated cash runway and the Company’s current expectations regarding its plans for future equity financings; the Company’s dependence on additional financing to fund its operations and complete the development and commercialization of its product candidates, and the risks that raising such additional capital may restrict the Company’s operations or require the Company to relinquish rights to the Company’s technologies or product candidates; the Company’s limited operating history in the Company’s current line of business, which makes it difficult to evaluate the Company’s prospects, the Company’s business plan or the likelihood of the Company’s successful implementation of such business plan; the timing for the Company or its partners to initiate the planned clinical trials for Versamune^® HPV, PDS01ADC and other Versamune^® and Infectimune^® based product candidates; the future success of such trials; the successful implementation of the Company’s research and development programs and collaborations, including any collaboration studies concerning Versamune^® HPV, PDS01ADC and other Versamune^® and Infectimune^® based product candidates and the Company’s interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Company’s product candidates; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund its disclosed clinical trials, which assumes no material changes to the Company’s currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim or preliminary results (including, without limitation, any preclinical results or data), which are not necessarily indicative of the final results of the Company’s ongoing clinical trials; any Company statements about its understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs and any collaboration studies; the Company’s ability to continue as a going concern; and other factors, including legislative, regulatory, political and economic developments not within the Company’s control. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the other risks, uncertainties, and other factors described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the U.S. Securities and Exchange Commission. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.  

Versamune^® and Infectimune^® are registered trademarks of PDS Biotechnology Corporation.

Keytruda^® is a registered trademark of Merck Sharp and Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, N.J., USA.

Xtandi^® is a registered trademark of Astellas Pharma Inc.

Investor Contact:
Mike Moyer
LifeSci Advisors
Phone +1 (617) 308-4306
Email: mmoyer@lifesciadvisors.com

Media Contact:
Janine McCargo
6 Degrees
Phone +1 (646) 528-4034
Email: jmccargo@6degreespr.com

View full release: HERE

Does a Company Need a PCAOB Audit to go Public?

Posted on November 14, 2024November 14, 2024 by slightbourne@noblecapitalmarkets.com

Sponsored Content – In Partnership with Grassi

Unlike private companies that may or may not need an annual audit of their financial statements for compliance or stakeholder purposes, all public companies do – and not just any audit. It must be conducted under the specific rules and regulations of the Public Company Accounting Oversight Board (PCAOB).

Many companies looking to go public have never been audited before. And if they were, the audit probably adhered to Generally Accepted Auditing Standards (GAAS), which are not accepted by the SEC. The differences between PCAOB and GAAS audits mainly lie in the auditor independence standards, level of regulatory scrutiny, and scope of details that the auditor’s opinion must address. An objective engagement quality review partner, separate from the engagement team, must also review and sign off on PCAOB audit results.

While CPA firms that audit private companies face periodic peer reviews, PCAOB-registered auditors face more heightened and frequent scrutiny. A PCAOB inspection is a rigorous inspection and public reporting of the audit results.

A PCAOB audit is required before a company can file with the SEC. If a private company has never been audited, it must provide PCAOB audits for at least the past two years. This additional work should be factored into the audit engagement timing relative to the target IPO timeline.

An audit can take anywhere from six weeks to several months, depending on the level of complexity and preparedness, but a company looking to go public should start the process much sooner. Leave enough time to get your company audit-ready with the help of a qualified CPA and public company reporting consultant.

A private company should ensure it has adequate internal resources to support the PCAOB audit process, which requires demanding engagement from accounting staff. This internal support should be maintained to meet the heavy reporting burden that comes with being a public company.

Certain financial data not required in private company audits must be compiled, including source documentation, evaluation of complex accounting transactions and technical accounting memorandums. One example is a capitalization (cap) table, a complex spreadsheet detailing all equity transactions, ownership stakes, types of shares and option pools.

The CPA will lead the audit process and serve as part of a larger team of advisors, including an investment banker and attorney, who will help your company manage and meet the many requirements of the SEC filing, IPO process and exchange listing.

Going public is not the only reason a private company would want a PCAOB audit. Another factor could be to make the company more attractive to potential public company buyers. Whatever the reason, it will be an adjustment for the company’s accounting staff. Reach out early and often to a PCAOB-registered audit firm that can guide you through the audit process and work collaboratively with your advisory team.

Grassi is an experienced PCAOB audit provider and ready to help your business. Contact us today to learn more about our SEC Accounting Services.

Unicycive Therapeutics (UNCY) – 3Q24 Reported With Progress Driven By OLC

Posted on November 14, 2024November 14, 2024 by cpereira@noblefcm.com

Thursday, November 14, 2024

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

OLC Achieved Significant Milestones In 3Q24. Unicycive reported a 3Q24 loss of $4.1 million or $(0.05) per share. During the quarter, the NDA was submitted for approval of oxylanthanum carbonate (OLC), its phosphate binder for patients on renal dialysis. After the close of the quarter, the acceptance for filing was announced with a PDUFA date of June 28, 2025. The quarter ended with $32.3 million in cash, which we believe is sufficient to fund operations and launch of OLC in 2025-26.

NDA Submission Was Completed As Expected. In early September, Unicycive submitted the new drug application (NDA) for OLC, its phosphate binder for patients on renal dialysis. On November 11, the company announced FDA acceptance of the application for review and assigned a PDUFA date of June 28, 2025. This is the statutory date for the FDA to answer the application with Market Approval or a denial known as a Complete Response Letter (CRL).

Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.

Snail (SNAL) – Clearing Up The Noise

Posted on November 14, 2024November 14, 2024 by cpereira@noblefcm.com

Thursday, November 14, 2024

Snail is a leading, global independent developer and publisher of interactive digital entertainment for consumers around the world, with a premier portfolio of premium games designed for use on a variety of platforms, including consoles, PCs and mobile devices.

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Q3 results. The company reported revenue of $22.5 million, largely in line with our estimate of $25.0 million, and Adj. EBITDA of $0.5 million, below our estimate of $4.0 million. Notably, results benefitted from the Aberration DLC release that was included in the sale of Ark: Survival Ascended (ASA), and part 2 of Bobs Tall Tales. Importantly, the adj. EBITDA miss was a largely a function of lower revenue, given the amount of fixed licensing expenses in its cost structure.

DLC release outlook. With the release of the Aberration DLC in September, there are three DLC packages that were included in the sale of ASA that have yet to be released. The next DLC is expected in Q4 and two more are expected in 2025. Importantly, as DLC packages included in ASA are released, the company will defer less revenue from ASA sales, which should provide investors with a clearer picture of company operating results.

Get the Full Report

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

DLH Holdings (DLHC) – A More Flexible Credit Facility

Posted on November 14, 2024November 14, 2024 by cpereira@noblefcm.com

Thursday, November 14, 2024

DLH delivers improved health and readiness solutions for federal programs through research, development, and innovative care processes. The Company’s experts in public health, performance evaluation, and health operations solve the complex problems faced by civilian and military customers alike, leveraging digital transformation, artificial intelligence, advanced analytics, cloud-based applications, telehealth systems, and more. With over 2,300 employees dedicated to the idea that “Your Mission is Our Passion,” DLH brings a unique combination of government sector experience, proven methodology, and unwavering commitment to public health to improve the lives of millions. For more information, visit www.DLHcorp.com.

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Credit Facility and CMOP Update. Yesterday, DLH announced the Company has amended its credit facility with lenders to modify the borrowing capacity of the facility itself and the financial covenants of the agreement. The credit facility’s maximum capacity is reduced from $70 million to $50 million with the amendment, although no changes were made to the maturity or pricing terms. We would point out that DLH also is expected to transition a portion of its CMOP locations to set-aside, small business contractors, although no further details were given.

Financial Covenants. As for the financial covenants of the agreement, the two that are specifically being changed are the Total Leverage ratio and Fixed Charge Coverage ratio. Importantly, the amendment increases the maximum threshold of the Total Leverage Ratio, with the most recent being to 4.5 to 1.0 in the first quarter next year from a prior 4.25 to 1.00. As for the Fixed Charge Coverage ratio, the minimum threshold is being lowered with the most recent staying the same at less than to 1.25 to 1.00 in the first quarter next year but lowering in subsequent quarters. While the reduction of the capacity of the facility is not ideal, we believe the changes to the covenants provides DLH flexibility in anticipation of the Company’s CMOP locations being moved to small businesses, impacting performance.

Get the Full Report

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

Cocrystal Pharma (COCP) – 3Q24 Reported With Data Announcements Ahead

Posted on November 14, 2024November 14, 2024 by cpereira@noblefcm.com

Thursday, November 14, 2024

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com.

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Two Trials Expected To Report Data Shortly. Cocrystal reported a 3Q24 loss of $4.9 million or $(0.49) per share. The company made progress in its clinical programs during the quarter, including CC42344, its oral PB2 inhibitor for seasonal and pandemic influenza. We see this an increasingly important product, given the spread of a new variant of the virus known as H5N1, or the avian flu. Data from its Phase 2a human challenge study is expected before year-end.

CC-42344 Could Be Effective Against The New Bird Flu. As discussed in our Research Note on June 21, a new virulent strain of influenza known as avian flu (H5N1) had been detected in dairy cattle. Earlier this year, the first infections in dairy workers showed the virus had mutated enough to begin infecting humans. Preclinical testing with CC-42344 showed it was able to inhibit the virus and has potential for human use against the strain.

Get the Full Report

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

Bitcoin Depot (BTM) – Building Momentum Ahead of 2025

Posted on November 14, 2024November 14, 2024 by cpereira@noblefcm.com

Thursday, November 14, 2024

Patrick McCann, CFA, Research Analyst, Noble Capital Markets, Inc.

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Q3 beat. The company reported solid Q3 results, beating our estimates on both revenue and adj. EBITDA. Q3 revenue was $135.3 million, better than our estimate of $130.6 million and adj. EBITDA was $9.2 million, better than our estimate of $7.8 million.

Kiosk re-deployment paying off. After focusing on re-deploying underperforming kiosks during 2023 and in the first half of 2024, the company’s kiosks appear to be gaining traction. This is evident in the median transaction size, which climbed from roughly $200 in the beginning of the year to $250 in Q3. Notably, it takes time for re-deployed kiosks to be discovered by potential users. As a result, newly deployed kiosks tend to have an initial drag on profitability.

Get the Full Report

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

Fed Chair Powell: No Rush to Cut Rates Amid Strong U.S. Economy

Posted on November 14, 2024November 14, 2024 by slightbourne@noblecapitalmarkets.com

Key Points:
– The Federal Reserve is in no hurry to reduce interest rates due to strong economic indicators.
– Chairman Powell emphasizes that inflation remains slightly above the 2% target.
– The Fed will approach future rate cuts cautiously, allowing flexibility based on economic signals.

Federal Reserve Chair Jerome Powell recently signaled that the central bank sees no need to accelerate interest rate cuts, pointing to the resilience of the U.S. economy. Speaking at a Dallas Fed event, Powell highlighted the strength in several key economic indicators—including sustained growth and low unemployment—while acknowledging that inflation remains slightly above the Federal Reserve’s target.

Currently, inflation sits just above the Fed’s preferred 2% target, with October’s Personal Consumption Expenditures (PCE) price index estimated at around 2.3%, while core PCE inflation, which excludes volatile food and energy prices, is anticipated to reach about 2.8%. Although inflation remains higher than the target, Powell emphasized the Fed’s confidence that the economy is on a “sustainable path to 2%” inflation, justifying a gradual, measured approach to any future rate adjustments.

Despite continued economic growth, which Powell described as “stout” at an annualized rate of 2.5%, and a stable job market with a 4.1% unemployment rate, the Fed is maintaining its flexibility. According to Powell, the ongoing strength of the economy allows the Fed to “approach our decisions carefully.” This measured stance contrasts with earlier expectations from financial markets, where investors had anticipated a series of rate cuts for the next year. Now, based on Powell’s remarks, these expectations are being recalibrated, and fewer cuts are anticipated.

The Fed’s cautious stance also reflects broader economic uncertainties as the U.S. awaits potential policy changes from President-elect Donald Trump’s incoming administration, particularly regarding tax cuts, tariffs, and immigration policy. These factors could impact inflation and growth in ways that are still unfolding. Investors are closely watching the economic outlook as they prepare for potential policy shifts that could influence both the domestic economy and inflationary pressures.

Powell’s comments come at a critical time as the Fed’s next policy meeting approaches on December 17-18, with many traders expecting a further quarter-point reduction. However, recent inflation and economic strength may lead the Fed to hold off on more aggressive cuts in the near future. Powell reiterated that the Fed is committed to reaching its inflation goals, stating, “Inflation is running much closer to our 2% longer-run goal, but it is not there yet,” underscoring the Fed’s careful monitoring of inflationary trends, including housing costs.

As markets adjust to the Fed’s deliberate approach, Powell’s emphasis on data-driven, cautious decision-making has given investors insight into the central bank’s priorities. With the economy sending no urgent signals for rate cuts, the Federal Reserve appears poised to balance economic stability with its commitment to achieving sustainable inflation, underscoring its willingness to act when necessary but not before.

TransAlta Finalizes Acquisition of Heartland Generation in $542 Million Deal

Posted on November 14, 2024November 14, 2024 by slightbourne@noblecapitalmarkets.com

Key Points:
– TransAlta acquires Heartland Generation for $542 million, adjusting for asset divestitures.
– Acquisition to add 1,747 MW of capacity, enhancing TransAlta’s Alberta portfolio.
– Deal expected to yield $85-$90 million in annual EBITDA and $20 million in annual synergies.

TransAlta Corporation announced an amended acquisition agreement to purchase Heartland Generation from Energy Capital Partners (ECP) at a revised price of $542 million. This agreement, which includes the assumption of $232 million of debt, strengthens TransAlta’s presence in Alberta’s energy market, adding diverse power generation assets critical for the province’s growing needs. The transaction is expected to close by December 4, 2024, and includes the divestiture of Heartland’s Poplar Hill and Rainbow Lake assets, which account for 97 MW of power. These divestitures, required to meet federal Competition Bureau guidelines, prompted an $80 million reduction in the purchase price and will allow TransAlta to focus on core, high-value assets in its portfolio.

Heartland Generation’s assets are strategically valuable to TransAlta. By adding 1,747 MW of capacity, including gas-fired and peaking generation, as well as cogeneration facilities, TransAlta will significantly enhance its energy capabilities. This expanded portfolio is expected to be highly accretive to the company’s cash flow, contributing an estimated $85 to $90 million in annual EBITDA post-synergies and divestitures. Approximately 60% of Heartland’s revenues are under long-term contracts with an average remaining life of 15 years, ensuring steady, reliable income from high-credit, stable clients. According to TransAlta, the acquisition will yield substantial free cash flow and achieve a cash yield backed by low-cost, high-efficiency energy generation, supporting Alberta’s dynamic power needs.

CEO John Kousinioris emphasized the alignment of this acquisition with TransAlta’s growth strategy in Alberta. “The pending acquisition of Heartland will allow TransAlta to incorporate high-demand generation capabilities, enhancing our role in supporting grid reliability. Consistent with our original investment thesis, the Alberta market will increasingly require low-cost, flexible, and fast-responding generation to support grid reliability over the coming years. This transaction supports our competitive position by ensuring we maintain a robust and diversified portfolio,” he noted. The deal allows TransAlta to better meet Alberta’s evolving energy demands and gain an edge in the market by offering reliable power that complements and balances renewable energy sources, particularly as renewables are scaled up across Alberta.

TransAlta will also leverage significant operational and financial synergies by integrating Heartland’s assets. The company expects $20 million in annual synergies through shared corporate and operational costs. With TransAlta’s existing assets, the expanded scale will enable supply chain efficiencies, operational optimizations, and additional synergies that will enhance margins and support long-term growth. Heartland’s portfolio, with critical infrastructure for future hydrogen development, is also well-suited to support sustainable initiatives, aligning with TransAlta’s commitment to advancing clean energy solutions.

The transaction metrics are favorable to TransAlta’s growth outlook, with an estimated $270 per kilowatt valuation for the Heartland assets. The acquisition’s 5.4 times EBITDA multiple positions TransAlta for long-term value creation through low-cost power generation assets that are increasingly valuable in Alberta’s shifting energy landscape. With the strategic advantages of this acquisition, TransAlta’s enhanced portfolio and market reach will play a vital role in securing Alberta’s energy future.

Charter to Acquire Liberty Broadband Corporation in $280M All-Stock Deal

Posted on November 14, 2024November 14, 2024 by slightbourne@noblecapitalmarkets.com

Key Points:
– Charter to acquire Liberty Broadband in a $280M all-stock transaction.
– Acquisition reduces Charter’s outstanding shares by 11.5 million.
– Key shareholders, including John Malone, support the strategic merger.

Charter Communications, Inc. (NASDAQ: CHTR) has entered into an agreement to acquire Liberty Broadband Corporation (NASDAQ: LBRDA, LBRDK, LBRDP) in an all-stock transaction valued at $280 million. This strategic acquisition will significantly enhance Charter’s reach in the U.S. broadband market, bringing together key assets and expanding its operational scale.

The terms of the agreement specify that Liberty Broadband shareholders will receive 0.236 shares of Charter common stock per share held, while preferred shareholders will gain new Charter preferred stock mirroring their current terms. A crucial aspect of the acquisition is Liberty’s plan to spin off its GCI subsidiary, Alaska’s largest communications provider, which serves remote and challenging regions. Charter will assume the tax liability for this spin-off if it exceeds $420 million, with closing anticipated by mid-2027 pending regulatory approvals and shareholder votes.

Charter expects to benefit from a net reduction of approximately 11.5 million shares by retiring the 45.6 million shares currently held by Liberty Broadband. Liberty’s existing debt of $2.6 billion will be addressed through repayment or assumption, alongside $180 million of preferred equity that will convert to Charter preferred equity upon closing.

Support from key shareholders, including John Malone and Greg Maffei, will play an essential role, with both expressing optimism for the merger’s potential. “This transaction simplifies our corporate structure, aligning with Charter’s long-term strategic goals,” said Malone. Greg Maffei, Liberty Broadband’s CEO, stated that the partnership offers substantial growth potential and value creation for both Charter and Liberty shareholders.

The Boards of both companies, alongside independent legal and financial advisors, have approved the merger, noting that the transaction will enhance market competitiveness while increasing liquidity for Liberty shareholders. Centerview Partners and Citi are advising Charter, while J.P. Morgan advises Liberty Broadband.

As Charter moves forward with this acquisition, the merger is expected to enhance shareholder value, increase access to communications services, and streamline governance processes for both companies.

Release – Tonix Pharmaceuticals Announces Poster Presentation at the American College of Rheumatology (ACR) Convergence 2024 Annual Meeting

Posted on November 13, 2024November 13, 2024 by aweinsoff@channelchek.com

Research News and Market Data on TNXP

November 13, 2024 4:05pm ESTDownload as PDF

CHATHAM, N.J., Nov. 13, 2024 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, will deliver a poster presentation at the ACR Convergence 2024 Annual Meeting, which will be held in Washington, D.C., November 14-19, 2024. A copy of the Company’s presentation will be available under the Scientific Presentations tab of the Tonix website at www.tonixpharma.com following the conference. Additional meeting information can be found on the ACR website here.

Presentation Details

Presenter:	Seth Lederman, M.D.

Title:	Randomized, Double-Blind, Placebo-Controlled Confirmatory Phase 3 Trial of Bedtime Sublingual Cyclobenzaprine (TNX-102 SL) in Fibromyalgia

Poster No.:	1218

Session:	Poster Session B, Pain in Rheumatic Disease Including Fibromyalgia Poster

Location:	Walter E. Washington Convention Center, Washington, D.C.

Date:	Sunday, November 17, 2024

Time:	10:30 a.m. – 12:30 p.m. ET

Tonix Pharmaceuticals Holding Corp.^*

Tonix is a fully-integrated biopharmaceutical company focused on transforming therapies for pain management and vaccines for public health challenges. Tonix’s development portfolio is focused on central nervous system (CNS) disorders. Tonix’s priority is to advance TNX-102 SL, a product candidate for the management of fibromyalgia, for which an NDA was submitted based on two statistically significant Phase 3 studies for the management of fibromyalgia. The FDA has granted Fast Track designation to TNX-102 SL for the management of fibromyalgia. We expect an FDA decision on the acceptance of the NDA for review and a PDUFA date in December and if accepted, a decision on NDA approval in 2025. TNX-102 SL is also being developed to treat acute stress reaction and acute stress disorder under a Physician-Initiated IND at the University of North Carolina in the OASIS study funded by the U.S. Department of Defense (DoD). Tonix’s CNS portfolio includes TNX-1300 (cocaine esterase), a biologic in Phase 2 development designed to treat cocaine intoxication that has FDA Breakthrough Therapy designation and its development is supported by a grant from the U.S. National Institute of Drug Abuse and Addiction. Tonix’s immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is an Fc-modified humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease, including TNX-2900 for Prader-Willi syndrome, and infectious disease, including a vaccine for mpox, TNX-801. Tonix recently announced a contract with the U.S. DoD’s Defense Threat Reduction Agency (DTRA) for up to $34 million over five years to develop TNX-4200, small molecule broad-spectrum antiviral agents targeting CD45 for the prevention or treatment of infections to improve the medical readiness of military personnel in biological threat environments. Tonix owns and operates a state-of-the art infectious disease research facility in Frederick, MD. Tonix Medicines, our commercial subsidiary, markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg for the treatment of acute migraine with or without aura in adults.

* Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.

Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. All other marks are property of their respective owners.

This press release and further information about Tonix can be found at www.tonixpharma.com.

Forward Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Toni’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the failure to successfully market any of our products; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission (the “SEC”) on April 1, 2024, and periodic reports filed with the SEC on or after the date thereof. All of Toni’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

Investor Contact

Jessica Morris
Tonix Pharmaceuticals
investor.relations@tonixpharma.com
(862) 904-8182

Peter Vozzo
ICR Healthcare
peter.vozzo@westwicke.com
(443) 213-0505

Media Contact

Ray Jordan
Putnam Insights
ray@putnaminsights.com
(949) 245-5432

Source: Tonix Pharmaceuticals Holding Corp.

Released November 13, 2024

Release – Bitcoin Depot Reports Third Quarter 2024 Financial Results

Posted on November 13, 2024November 13, 2024 by aweinsoff@channelchek.com

Research News and Market Data on BTM

November 13, 2024 8:05 AM EST Download as PDF

ATLANTA, Nov. 13, 2024 (GLOBE NEWSWIRE) — Bitcoin Depot Inc. (“Bitcoin Depot” or the “Company”), a U.S.-based Bitcoin ATM operator and leading fintech company, today reported financial results for the third quarter ended September 30, 2024. Bitcoin Depot will host a conference call and webcast at 10:00 a.m. ET today. An earnings presentation and link to the webcast will be made available at ir.bitcoindepot.com.

“During the third quarter, we made significant strides in expanding our Bitcoin ATM network while working to optimize existing machines for greater profitability,” said Brandon Mintz, CEO and Founder of Bitcoin Depot. “We ended the quarter with 8,300 machines, surpassing our goals and reflecting our team’s execution and vision to enhance Bitcoin’s accessibility.

“In the past year, we’ve focused on relocating underperforming BTMs to more promising locations, a strategy that historically boosts average profitability per kiosk over time. While this improvement may not be fully visible in our consolidated quarterly numbers, the strategy is proving effective. With our extensive kiosk footprint and these initiatives in place, we are confident in our ability to drive shareholder value moving forward.

“As a result of our continued cash flow generation, we believe that beginning a cash dividend to common shareholders in 2025 will be one of the ways we create value for shareholders.”

Third Quarter 2024 Financial Results

Revenue in the third quarter of 2024 was $135.3 million, down 25% from $179.5 million in the third quarter of 2023. This decline was largely driven by the impact of unfavorable legislation that was passed in California that went into effect in January 2024, along with the Company’s continued process of relocating underperforming kiosks in order to optimize fleet profitability.

Total operating expenses declined 13% to $16.9 million for the third quarter of 2024, compared to $19.5 million for the third quarter of 2023 due to costs of going public in 2023 that did not recur in 2024.

Net income for the third quarter of 2024 increased 116% to $2.3 million, compared to net income of $1.1 million for the third quarter of 2023. The increase was due to lower operating expenses in 2024, and expenses associated with the PIPE financing in the third quarter of 2023 that did not recur in 2024.

Adjusted gross profit, a non-GAAP measure, in the third quarter of 2024 was $22.4 million, down 17% from $26.9 million for the third quarter of 2023. Adjusted gross profit margin, a non-GAAP measure, in the third quarter of 2024 increased approximately 160 basis points to 16.6% compared to 15.0% in the third quarter of 2023. Please see “Explanation and Reconciliation of Non-GAAP Financial Measures” below.

Adjusted EBITDA, a non-GAAP measure, in the third quarter of 2024 decreased 34% to $9.2 million, compared to Adjusted EBITDA of $13.9 million for the third quarter of 2023. The decline was due to the lower revenue. Please see “Explanation and Reconciliation of Non-GAAP Financial Measures” below.

Cash and cash equivalents were $32.2 million as of the end of the third quarter of 2024. The Company generated $5.8 million in cash flows from operations in the third quarter and $17.3 million for the first nine months of 2024.

During the third quarter of 2024, the Company generated $5.8 million of cash flow from operations compared to $7.0 million in the third quarter of 2023.

Conference Call

Bitcoin Depot will hold a conference call at 10:00 a.m. Eastern time (7:00 a.m. Pacific time) today to discuss its financial results for the third quarter ended September 30, 2024.

Call Date: Wednesday, November 13, 2024
Time: 10:00 a.m. Eastern time (7:00 a.m. Pacific time)
U.S. dial-in: 646-968-2525
International dial-in: 888-596-4144
Conference ID: 7631242

The conference call will broadcast live and be available for replay here following the call.

Please call the conference telephone number approximately 10 minutes before the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact Bitcoin Depot’s investor relations team at 1-949-574-3860.

A replay of the call will be available beginning after 2:00 p.m. Eastern time on November 13, 2024, through November 20, 2024.

U.S. replay number: 609-800-9909
International replay number: 800-770-2030
Conference ID: 7631242

About Bitcoin Depot

Bitcoin Depot Inc. (Nasdaq: BTM) was founded in 2016 with the mission to connect those who prefer to use cash to the broader, digital financial system. Bitcoin Depot provides its users with simple, efficient and intuitive means of converting cash into Bitcoin, which users can deploy in the payments, spending and investing space. Users can convert cash to bitcoin at Bitcoin Depot kiosks in 48 states and at thousands of name-brand retail locations in 29 states through its BDCheckout product. The Company has the largest market share in North America with approximately 8,300 kiosk locations as of September 30, 2024. Learn more at www.bitcoindepot.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release and any oral statements made in connection herewith include “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange Act of 1934, as amended. Forward-looking statements are any statements other than statements of historical fact, and include, but are not limited to, statements regarding the expectations of plans, business strategies, objectives and growth and anticipated financial and operational performance, including our growth strategy and ability to increase deployment of our products and services, our ability to strengthen our financial profile, and worldwide growth in the adoption and use of cryptocurrencies. These forward-looking statements are based on management’s current beliefs, based on currently available information, as to the outcome and timing of future events. Forward-looking statements are often identified by words such as “anticipate,” “appears,” “approximately,” “believe,” “continue,” “could,” “designed,” “effect,” “estimate,” “evaluate,” “expect,” “forecast,” “goal,” “initiative,” “intend,” “may,” “objective,” “outlook,“ ”plan,“ ”potential,“ ”priorities,“ ”project,“ ”pursue,“ ”seek,“ ”should,“ ”target,“ ”when,“ ”will,“ ”would,” or the negative of any of those words or similar expressions that predict or indicate future events or trends or that are not statements of historical matters, although not all forward-looking statements contain such identifying words. In making these statements, we rely upon assumptions and analysis based on our experience and perception of historical trends, current conditions, and expected future developments, as well as other factors we consider appropriate under the circumstances. We believe these judgments are reasonable, but these statements are not guarantees of any future events or financial results. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond our control.

These forward-looking statements are subject to a number of risks and uncertainties, including changes in domestic and foreign business, market, financial, political and legal conditions; failure to realize the anticipated benefits of the business combination; risks relating to the uncertainty of our projected financial information; future global, regional or local economic and market conditions; the development, effects and enforcement of laws and regulations; our ability to manage future growth; our ability to develop new products and services, bring them to market in a timely manner and make enhancements to our platform; the effects of competition on our future business; our ability to issue equity or equity-linked securities; the outcome of any potential litigation, government and regulatory proceedings, investigations and inquiries; and those factors described or referenced in filings with the Securities and Exchange Commission. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that we do not presently know or that we currently believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect our expectations, plans or forecasts of future events and views as of the date of this press release. We anticipate that subsequent events and developments will cause our assessments to change.

We caution readers not to place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date they are made, and we undertake no obligation to update publicly or otherwise revise any forward-looking statements, whether as a result of new information, future events, or other factors that affect the subject of these statements, except where we are expressly required to do so by law. All written and oral forward-looking statements attributable to us are expressly qualified in their entirety by this cautionary statement.

Explanation and Reconciliation of Non-GAAP Financial Measures

Bitcoin Depot reports its financial results in accordance with accounting principles generally accepted in the United States of America (“GAAP”). This press release includes both historical and projected Adjusted EBITDA, Adjusted Gross Profit, and certain ratios and other metrics derived therefrom such as Adjusted EBITDA margin and Adjusted Gross Profit margin, which are not prepared in accordance with GAAP.

Bitcoin Depot defines Adjusted EBITDA as net income before interest expense, income tax expense, depreciation and amortization, non-recurring expenses, share-based compensation, expenses related to the PIPE financing and miscellaneous cost adjustments. Such items are excluded from Adjusted EBITDA because these items are non-cash in nature, or because the amount and timing of these items is unpredictable, not driven by core results of operations and renders comparisons with prior periods and competitors less meaningful. In addition, Bitcoin Depot defines Adjusted Gross Profit (a non-GAAP financial measure) as revenue less cost of revenue (excluding depreciation and amortization) and depreciation and amortization adjusted to add back depreciation and amortization. Bitcoin Depot believes Adjusted EBITDA and Adjusted Gross Profit each provide useful information to investors and others in understanding and evaluating Bitcoin Depot’s results of operations, as well as provide a useful measure for period-to-period comparisons of Bitcoin Depot’s business performance. Adjusted EBITDA and Adjusted Gross Profit are each key measurements used internally by management to make operating decisions, including those related to operating expenses, evaluate performance and perform strategic and financial planning. However, you should be aware that Adjusted EBITDA and Adjusted Gross Profit are not measures of financial performance calculated in accordance with GAAP and may exclude items that are significant in understanding and assessing Bitcoin Depot’s financial results, and further, that Bitcoin Depot may incur future expenses similar to those excluded when calculating these measures. Bitcoin Depot primarily relies on GAAP results and uses both Adjusted EBITDA and Adjusted Gross Profit on a supplemental basis. Neither Adjusted EBITDA or Adjusted Gross Profit should be considered in isolation from, or as an alternative to, net income, cash flows from operations or other measures of profitability, liquidity or performance under GAAP and may not be indicative of Bitcoin Depot’s historical or future operating results. Bitcoin Depot’s computation of both Adjusted EBITDA and Adjusted Gross Profit may not be comparable to other similarly titled measures computed by other companies because not all companies calculate such measures in the same fashion. As such, undue reliance should not be placed on such measures.

Due to the high variability and difficulty in making accurate forecasts and projections of some of the information excluded from the projections of Adjusted EBITDA, together with some of the excluded information not being ascertainable or accessible, Bitcoin Depot is unable to quantify certain amounts that would be required to be included in the most directly comparable GAAP financial measures without unreasonable effort. Consequently, no disclosure of estimated comparable GAAP measures is included and no reconciliation of the forward-looking non-GAAP financial measures is included.

The following table presents a reconciliation of Net (loss) income to Adjusted EBITDA for the periods indicated:

Contacts:

Investors
Cody Slach,
Gateway Group, Inc.
949-574-3860
BTM@gateway-grp.com

Media
Zach Kadletz, Brenlyn Motlagh, Ryan Deloney
Gateway Group, Inc.
949-574-3860
BTM@gateway-grp.com

Source: Bitcoin Depot Inc.

Released November 13, 2024